scholarly journals Effect Covid-19: Burnout on nurse

2020 ◽  
Vol 41 (42) ◽  
Author(s):  
Hardiyono HARDIYONO ◽  
◽  
Ikhram AIYUL ◽  
Finatry IFAH ◽  
Wahdaniaht WAHDANIAH ◽  
...  

This study aims to determine the impact of the Covid-19 pandemic on burnout experienced by nurses at Dr. Hospital. Wahidin Sudirohusodo as one of the special hospitals that treat patients affected by Covid-19. This research is a qualitative study using some literature from related articles and journals as well as the results of a discussion group forum (FGD) from nurses at Dr. Wahidin Sudirohusodo Hospital Makassar. The results showed that there was a burnout in nurses when they saw so many patients who were under observation or who were positively affected by the outbreak of this virus. Nurses are confronted with thoughts of high-risk work amid pandemic conditions and think of families who are at home as well as conditions where nurses want to go home but workloads are very high and worry about returning home in conditions carrying viruses that are invisible. Limitations of this study are the lack of access to communicate with nurses who maintain contact with researchers at the time to prevent the spread of the virus.

2019 ◽  
Vol 3 (2) ◽  
Author(s):  
Indah Fionita ◽  
Iwan Juwana

ABSTRAKKota Cimahi merupakan salah satu kota di Jawa Barat yang masih menghadapi permasalahan persampahan, seperti terbatasnya penerapan kegiatan pemilahan sampah, terbatasnya jumlah Tempat Penampungan Sementara (TPS), terjadi pembuangan sampah secara sembarangan ke sungai, terdapat penanganan sampah dengan cara dibakar dan ditimbun, dan lain-lain. Dalam menindaklanjuti berbagai permasalahan sampah tersebut serta mencapai target 30% pengurangan sampah yang ditentukan oleh Kebijakan Strategis Nasional (Jakstranas), maka diperlukan suatu instrumen yang mampu menganalisis area berisiko berdasarkan tingkat risiko persampahan per kelurahan di Kota Cimahi. Area berisiko tersebut digambarkan dalam bentuk peta dengan mengacu pada pedoman Strategi Sanitasi Kabupanen/Kota (SSK) 2018. Area berisiko dinilai melalui skor 1 s.d. 4 secara berturut-turut untuk risiko sangat rendah, rendah, tinggi, dan sangat tinggi. Skor tersebut diperoleh dengan mengalikan parameter Impact dan parameter Exposure. Hasil penelitian ini menunjukkan terdapat tiga kelurahan dengan risiko persampahan sangat tinggi, yaitu Kelurahan Cibeureum, Setiamanah, dan Padasuka serta satu kelurahan dengan risiko persampahan tinggi, yaitu Kelurahan Melong. Penambahan jumlah unit pengolahan direkomendasikan di beberapa kelurahan sehingga terjadi perubahan skor area berisiko.Kata Kunci: Kota Cimahi, Peta Area Berisiko, Persampahan ABSTRACTCimahi City is one of the cities in West Java that still faces solid waste problems, such as the limited implementation of waste sorting activities, the limited number of temporary shelter sites, the indiscriminate waste disposal on river, open burning of solid waste, etc. In following up on these various waste problems and achieving the target of 30% waste reduction determined by the National Strategic Policy, an instrument is needed to analyze risk areas based on the level of risk of solid waste per village in Cimahi City. These risk areas are depicted in the form of maps by referring to the 2018 District/City Sanitation Strategy Guidelines. Risk areas are assessed through a score of 1 s.d. 4 for very low, low, high and very high risks. The score is obtained by multiplying the Impact parameters and Exposure parameters. The results of this study indicate that there are three villages with very high risk of solid waste, namely Kelurahan Cibeureum, Setiamanah, and Padasuka and one village with high risk of solid waste, namely Kelurahan Melong. The addition of the number of processing units was recommended in several villages so that changes in the score of risk areas occurred. Keyword: Cimahi City, Map of Risk Areas, Waste Solid


Author(s):  
Marion H. Hall

In Britain, antenatal care is performed by specialist obstetricians, general practitioners (GPs), and midwives, often in combination. Because most women are delivered in specialist hospitals, obstetricians are involved in booking for place of delivery, and usually in delivery of specialized investigations such as ultrasonic scanning. General practitioners may independently book women for confinement under their care in Cottage Hospitals or (rarely) at home, and may provide all the medical care for those women, in addition to sharing in the antenatal care of women to be delivered at specialist units, and in fact doing most of the care for these women, unless they are very high risk or complicated.


Brachytherapy ◽  
2018 ◽  
Vol 17 (4) ◽  
pp. S18
Author(s):  
Amishi Bajaj ◽  
Brendan Martin ◽  
Alexander Harris ◽  
Derrick Lock ◽  
Matthew M. Harkenrider ◽  
...  

2021 ◽  
Author(s):  
Valéria Verebová ◽  
Jana Staničová

Insecticides are among the most widely used pesticides in the world. They are preparations of chemical and biological origin used to control insects, which means its killing or preventing its destructive activity. Majority are used in forestry, agriculture, and households. Neonicotinoids represent the class of insecticides that is most frequently used in the world and replaced by more dangerous pyrethroids, organophosphates, and carbamates. In recent years, the focus has been mainly on the ecological and environmental risks caused by the use of neonicotinoids. These insecticides pose a very high risk to bees and also to soil and aquatic organisms. It is therefore highly topical to address the impact of neonicotinoids on biological systems on individual bio-macromolecules (DNA and serum albumins). Monitoring the impact of neonicotinoids on the structure and stability of biological macromolecules may contribute to reducing the use of these insecticides, as well as to considering and adjusting the tolerances of insecticides and their residues in food.


2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
J Brito ◽  
J.R Agostinho ◽  
C Duarte ◽  
B Silva ◽  
S Pereira ◽  
...  

Abstract Introduction Metabolic control plays an important role on major cardiovascular events (MACE) prevention. The 2019 ESC guidelines on dyslipidaemia management recommend tighter LDL-cholesterol (LDL-C) control in order to prevent cardiovascular events. However, it is not yet proven that thigh control of dyslipidaemia, glycaemic levels and body mass index (BMI) in Heart Failure (HF) patients (pts) have an impact on prognosis. Objective To evaluate the impact of LDL-C, HbA1c and BMI values on HF pts mortality and MACE rates. Methods Single centre study that included consecutive pts hospitalized for acute / decompensated chronic HF in a tertiary Hospital between January 2016 to December 2018 and followed for 12 months. The impact of LDL-C, HbA1c and BMI on mortality and MACE was assessed using Cox regression and Kaplan-Meier curve, after adjustment for age, sex, functional class and ejection fraction. A safety cut-off was established when any of these variables was deemed protective using ROC curve analysis. Results Two hundred twenty-four patients (71.68±13.45 years, 63.8% males) were included. Eighty-four (37.5%) pts had type 2 diabetes, 39.7% had ischemic heart disease and the median left ventricular ejection fraction was 34% (IQR 25–49.5; 60.3% HFrEF; 13.8% HFmrEF; 22.3% HFpEF). The median BMI was 25.4 kg/m2 (IQR 23.1–30.5), HbA1c, 6.4% (IQR 5.6–6.8) and LDL-C, 89.5 mg/dL (IQR 64–106); 145 (64.7%) pts were medicated with statins. The overall mortality and MACE rates during follow-up were 16.1% and 21.0%, respectively. According to the CV risk classification 39.7% pts were at very high risk and 19.6% pts at high risk. On multivariate analysis HbA1c (HR 1.5 IQR 1.1–1.9; p=0.007) and female sex (HR 9.453 IQR 2.4–37.2; p=0.001) were independent predictors of mortality, whereas LDL-C (OR 1.05 IQR 1.022–1.075; p<0.001) and BMI (OR 1.23 IQR 1.075–1.404; p=0.002) were independent protective factors. LDL-C and BMI had no effect on MACE rates, although HbA1c was an independent predictor of MACE (HR 1.27 IQR 1.03–1.57; p=0.026). For high and very high-risk pts there was still a protective trend on mortality, although non-significant, for higher levels of LDL-C (OR 1.04 IQR 0.99–1.075; P=NS). Protective LDL-C cut-off were estimated for the whole population (LDL-C 88mg/dL; AUC 0.819; sn 56.6%, sp 100%) and for the high and very-high CV risk pts (LDL-C 84mg/dL; AUC 0.815; sn 59.3%; sp 100%). A BMI safety cut-off for mortality of 25.75 kg/m2 was found (AUC 0.627; sn 61.2%; sp 58.3%). Conclusion This study supports the theory of the obesity and LDL-C paradox in HF. Lower LDL-C and BMI increased mortality and there is no trade-off effect on MACE rates, supporting the idea that LDL-C and BMI should not be aggressively addressed in HF pts. In our cohort a cut-off level of LDL-C below 88mg/dL is associated with higher mortality. On the other hand, diabetes should be actively treated as HbA1c predicts death and MACE in HF pts. Funding Acknowledgement Type of funding source: None


2014 ◽  
Vol 121 (6) ◽  
pp. 1314-1322 ◽  
Author(s):  
Pedro A. Gómez ◽  
Javier de-la-Cruz ◽  
David Lora ◽  
Luis Jiménez-Roldán ◽  
Gregorio Rodríguez-Boto ◽  
...  

Object Traumatic brain injury (TBI) represents a large health and economic burden. Because of the inability of previous randomized controlled trials (RCTs) on TBI to demonstrate the expected benefit of reducing unfavorable outcomes, the IMPACT (International Mission on Prognosis and Analysis of Clinical Trials in TBI) and CRASH (Corticosteroid Randomisation After Significant Head Injury) studies provided new methods for performing prognostic studies of TBI. This study aimed to develop and externally validate a prognostic model for early death (within 48 hours). The secondary aim was to identify patients who were more likely to succumb to an early death to limit their inclusion in RCTs and to improve the efficiency of RCTs. Methods The derivation cohort was recruited at 1 center, Hospital 12 de Octubre, Madrid (1990–2003, 925 patients). The validation cohort was recruited in 2004–2006 from 7 study centers (374 patients). The eligible patients had suffered closed severe TBIs. The study outcome was early death (within 48 hours post-TBI). The predictors were selected using logistic regression modeling with bootstrapping techniques, and a penalized reduction was used. A risk score was developed based on the regression coefficients of the variables included in the final model. Results In the validation set, the final model showed a predictive ability of 50% (Nagelkerke R2), with an area under the receiver operating characteristic curve of 89% and an acceptable calibration (goodness-of-fit test, p = 0.32). The final model included 7 variables, and it was used to develop a risk score with a range from 0 to 20 points. Age provided 0, 1, 2, or 3 points depending on the age group; motor score provided 0 points, 2 (untestable), or 3 (no response); pupillary reactivity, 0, 2 (1 pupil reacted), or 6 (no pupil reacted); shock, 0 (no) or 2 (yes); subarachnoid hemorrhage, 0 or 1 (severe deposit); cisternal status, 0 or 3 (compressed/absent); and epidural hematoma, 0 (yes) or 2 (no). Based on the risk of early death estimated with the model, 4 risk of early death groups were established: low risk, sum score 0–3 (< 1% predicted mortality); moderate risk, sum score 4–8 (predicted mortality between 1% and 10%); high risk, sum score 9–12 (probability of early death between 10% and 50%); and very high risk, sum score 13–20 (early mortality probability > 50%). This score could be used for selecting patients for clinical studies. For example, if patients with very high risk scores were excluded from our study sample, the patients included (eligibility score < 13) would represent 80% of the original sample and only 23% of the patients who died early. Conclusions The combination of Glasgow Coma Scale score, CT scanning results, and secondary insult data into a prognostic score improved the prediction of early death and the classification of TBI patients.


2020 ◽  
Vol 56 (1) ◽  
pp. 257-266
Author(s):  
Jean-Hugues Dalle ◽  
Adriana Balduzzi ◽  
Peter Bader ◽  
Anna Pieczonka ◽  
Isaac Yaniv ◽  
...  

AbstractAllogeneic HSCT represents the only potentially curative treatment for very high risk (VHR) ALL. Two consecutive international prospective studies, ALL-SCT-(I)BFM 2003 and 2007 were conducted in 1150 pediatric patients. 569 presented with VHR disease leading to any kind of HSCT. All patients >2 year old were transplanted after TBI-based MAC. The median follow-up was 5 years. 463 patients were transplanted from matched donor (MD) and 106 from mismatched donor (MMD). 214 were in CR1. Stem cell source was unmanipulated BM for 330 patients, unmanipulated PBSC for 135, ex vivo T-cell depleted PBSC for 62 and cord-blood for 26. There were more advanced disease, more ex vivo T-cell depletion, and more chemotherapy based conditioning regimen for patients transplanted from MMD as compared to those transplanted from MSD or MD. Median follow up (reversed Kaplan Meier estimator) was 4.99 years, median follow up of survivals was 4.88, range (0.01–11.72) years. The 4-year CI of extensive cGvHD was 13 ± 2% and 17 ± 4% (p = NS) for the patients transplanted from MD and MMD, respectively. 4-year EFS was statistically better for patients transplanted from MD (60 ± 2% vs. 42 ± 5%, p < 0.001) for the whole cohort. This difference does not exist if considering separately patients treated in the most recent study. There was no difference in 4-year CI of relapse. The 4-year NRM was lower for patients transplanted from MD (9 ± 1% vs. 23 ± 4%, p < 0.001). In multivariate analysis, donor-type appears as a negative risk-factor for OS, EFS, and NRM. This paper demonstrates the impact of donor type on overall results of allogeneic stem cell transplantation for very-high risk pediatric acute lymphoblastic leukemia with worse results when using MMD stem cell source.


Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 293-293
Author(s):  
Mareike Rasche ◽  
Emma Steidel ◽  
Denise Kondryn ◽  
Nils Von Neuhoff ◽  
Lucie Sramkova ◽  
...  

BACKGROUND: A risk-adapted approach incorporating genetic data, complemented by response evaluation may help to identify patients with high-risk disease (HR) who could benefit from hematopoietic stem cell transplantation (HSCT) at initial disease. Several international study groups currently recommend HSCT in pediatric HR AML. However, the impact of a risk-adapted treatment strategy is unknown. Here, we present results of our first treatment period with a risk-adapted indication for HSCT in the AML-BFM study group. PATIENTS AND METHOD: From 2012 until 2017 a total of 324 children &lt;18 years of the AML-BFM registry 2012 (hereafter named R12; Germany, Austria and Czech Republic) with de novo AML were included. Down syndrome or secondary leukemia, FAB M3, an accompanying disease or pre-treatment &gt;14 days were excluded. Patients or guardians provided written informed consent. Treatment guidelines were recommended but were not obligatory: Chemotherapy followed the best arm of study AML-BFM 2004, but patients were stratified according to new genetic and response-adapted (≥10% leukemic blasts after induction 1 or ≥5% after induction 2) risk criteria with the indication of HSCT in HR patients. We used AML-BFM 2004 (hereafter called S04) as historical comparison. The analysis was performed following the Declaration of Helsinki. Five-year estimates of overall survival (pOS) and event-free survival (pEFS) were calculated using SPSS (version 25). EFS is defined as the time from diagnosis to the first event (relapse, death, failure to achieve remission or secondary malignancy) or until last follow-up. Data were frozen on May 1st, 2019. RESULTS: We sought to systematically decipher the impact of a risk-adapted approach in pediatric AML. The total cohort showed a pEFS of 58±5% and pOS of 78±3% (vs S04 52±2%, p=0.014 and 70±2%, p=0.059) and significantly increased rates of HSCT (S04 vs R12: p&lt;0.001). Importantly, the SR group did not change between periods. The increase in survival was rather explained by improvements in patients with genetically defined HR AML resulting in a survival similar to IR AML (pEFS IR vs HR: p=0.684; pOS: p=0.861). Next, we compared outcome of a previously well-defined subgroup with rare very high-risk criteria (VHR). The risk-adapted therapy resulted in a significantly higher pEFS (S04 vs R12: 33±5% vs 48±11; p=0.017) and higher rates of HSCT (37% vs 78%, p&lt;0.001). Nevertheless, salvage treatment was equally efficient in both periods, resulting in a pOS of 56±6% vs 72±7% (p=0.202). To evaluate the effects of inclusion of response to mere genotype-driven stratification we reanalyzed all R12 patients retrospectively according to their genetic risk only (see table 1). Response-guided re-stratification led to major shifts of patients to higher risk groups. Importantly, despite the fact that the registry made only recommendations according to the new risk stratification, compliance with guidelines including HSCT indication was very high (n=319; 98%). Discrepancies were as follows: SR have been treated with a higher intensity (i.e. more chemotherapy and/or HSCT; n=2); HR AML treated as IR (n=2), IR AML received HR treatment including HSCT (n=2). Seventy-five percent of HR AML have been transplanted. Discrepancies are explainable by early relapses or death before HSCT. To validate the response-guided re-stratification more specifically, we performed a subgroup analysis of HR AML: The survival was similar in re-stratified IR patients and genetic HR patients with poor response (p=0.656) but was higher in genetic HR patients with good response (p=0.01), indicating an effective selection of re-stratified patients with IR. CONCLUSION: This analysis indicates the benefit of risk-adapted indications for HSCT in pediatric AML: After a long period with a stable pEFS (Rasche et al. Leukemia 2018) the current cohort now demonstrates a significant improvement. The efficacy of the risk-adapted approach is reflected by remarkable survival rates for patients with HR AML. At the same time, it seems not to impair the ongoing improvement of salvage therapy. However, for patients with poorly responding IR AML the outcome is dismal despite HSCT and they require alternative treatment approaches. Further studies are also needed to detect genetically defined HR patients who may not need HSCT, but also to develop efficient re-stratification approaches to enhance the survival in SR patients. Table 1. Disclosures Reinhardt: Novartis: Other: Participation in Advisory Boards; Roche: Research Funding; CSL Behring: Research Funding; Jazz: Other: Participation in Advisory Boards, Research Funding.


Sign in / Sign up

Export Citation Format

Share Document